Roivant Sciences (NASDAQ:ROIV) Shares Gap Up – What’s Next?

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) gapped up prior to trading on Wednesday . The stock had previously closed at $28.21, but opened at $29.60. Roivant Sciences shares last traded at $31.7910, with a volume of 2,079,051 shares.

Wall Street Analysts Forecast Growth

ROIV has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Roivant Sciences in a research note on Friday, May 8th. Citigroup upped their price target on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. HC Wainwright upped their price target on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, Guggenheim upped their price target on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $30.55.

Roivant Sciences Stock Performance

The firm has a market capitalization of $23.19 billion, a PE ratio of -27.70 and a beta of 1.14. The company has a fifty day moving average price of $28.38 and a 200-day moving average price of $24.85.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Thursday, May 21st. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.54. Roivant Sciences had a negative return on equity of 19.04% and a negative net margin of 6,079.94%.During the same quarter in the previous year, the business posted ($0.29) EPS. On average, equities analysts predict that Roivant Sciences Ltd. will post -1.55 earnings per share for the current year.

Insider Buying and Selling at Roivant Sciences

In other news, Director Melissa B. Epperly sold 41,861 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the sale, the director directly owned 15,804 shares of the company’s stock, valued at $453,258.72. This represents a 72.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Frank Torti sold 587,390 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $27.51, for a total value of $16,159,098.90. Following the sale, the insider directly owned 13,736,547 shares in the company, valued at $377,892,407.97. This trade represents a 4.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 3,745,173 shares of company stock worth $103,639,917. Company insiders own 10.80% of the company’s stock.

Institutional Trading of Roivant Sciences

Several hedge funds have recently modified their holdings of ROIV. Morgan Stanley raised its holdings in Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the period. Vanguard Group Inc. raised its holdings in Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after buying an additional 3,254,113 shares during the period. Rubric Capital Management LP raised its holdings in Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after buying an additional 2,603,260 shares during the period. State Street Corp raised its holdings in Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after buying an additional 911,827 shares during the period. Finally, UBS Group AG raised its holdings in Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.